非瓣膜性心房颤动患者卒中预防中的抗凝治疗

Anticoagulation therapy for stroke prevention in patients with nonvalvular atrial fibrillation

非瓣膜性心房颤动患者是缺血性卒中的高危人群，临床上主要采用抗凝治疗预防其卒中的发生。然而，常规口服抗凝药华法林因某些限制存在一定的困难。一些新型口服抗凝药，如直接凝血酶抑制药、凝血因子Xa抑制药在非瓣膜性心房颤动患者的卒中预防中显示了其前途。

Patients with nonvalvular atrial fibrillation are the high-risk population of isehemic stroke. Anticoagulation therapy is mainly used to prevent the occurrence of stroke in clinical practice, However, there are some difficulties in the conventional administration of oral antienagdant warfarin because of some restrictions. There are a number of novel oral anticoagulants with promising data for the prevention of stroke in nonvalvular atrial fibrillation, such as direct thrombin inhibitor and coa^lant factor X a inhibitor.